Verona Pharma plc: Grant of Options to PDMR
November 27, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Nov. 27, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that, on November 26,...
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
November 18, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr....
Verona Pharma plc: PDMR Dealing – Purchase by Chairman
November 14, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that Dr....
Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
November 13, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
November 11, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Nov. 11, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2019
November 05, 2019 02:00 ET
|
Verona Pharma plc
Reported positive Phase 2 data with dry powder inhaler formulation Post period end, completed enrollment in Phase 2b study with nebulized ensifentrine as add-on to long-acting bronchodilator LONDON,...
Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update
October 29, 2019 03:00 ET
|
Verona Pharma plc
LONDON, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, today announces...
Verona Pharma Completes Enrollment in Phase 2b Clinical Trial with Nebulized Ensifentrine in moderate-to-severe COPD
October 17, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it has randomized...
Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019
October 15, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...
Verona Pharma to Present Phase 2 Data with Ensifentrine Dry Powder Inhaler Formulation in COPD at European Respiratory Society International Congress 2019
September 19, 2019 02:00 ET
|
Verona Pharma plc
LONDON, Sept. 19, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, announces that it will present...